Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VBDD in Refractory or Relapsed Multiple Myeloma
NCT01394354Phase 2Completed
- Sponsor
- University Hospital Freiburg
- Start
- Aug 2011
- Primary completion
- Dec 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in multiple myeloma (MM), sponsored by University Hospital Freiburg. Started Aug 2011; status: completed.
02
Drugs
vorinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01394354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01394354.